SEARCH

SEARCH BY CITATION

References

  • 1
    Greenberg PD, Finch RJ, Gavin MA et al. Gene modification of T-cell clones for therapy of human viral and malignant diseases. Cancer J Sci Am 1999;S1: 1005.
  • 2
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;247: 23841.
  • 3
    Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2: 5515.
  • 4
    Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 1998;146: 2795894.
  • 5
    Rickinson AB, Kieff E. Epstein-Barr virus. In: FieldsBN, KnipeDM, HowleyPM, eds. Fields Virology. Philadelphia: Lippincott-Raven Publishers, 1996, 2397446.
  • 6
    Ambinder RF, Orentas RJ, Robertson KD. Epstein-Barr virus and Hodgkin's disease. In: ArmitageJ, NewlandA, KeatingA, BurnettA, eds. Cambridge Medical Reviews. Cambridge: Cambridge University Press, 1995, 120.
  • 7
    Lee SP, Chan ATC, Cheung S-T et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of tumor cells. J Immunol 2000;165: 57382.
  • 8
    De Campos-Lima PO, Levitskaya J, Frisan T, Masucci M. Strategies of immunoescape in Epstein-Barr virus persistence and pathogenesis. Semin Virol 1996;7: 7582.
  • 9
    Moss DJ, Burrows SR, Khanna R. Potential antigenic targets on Epstein-Barr virus-associated tumors and the host response. In: ChadwickDJ, MarshJ, eds. Vaccines Against Virally Induced Cancers. New York: John Wiley and Sons, 1994, 420.
  • 10
    Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol 2001;98: 2208.
  • 11
    Lee SP, Thomas WA, Blake NW, Rickinson AB. Transporter (TAP) -independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur J Immunol 1996;26: 187583.
  • 12
    Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 1987;139: 38027.
  • 13
    Zeijlemaker WP, Van Oers RHJ, De Goede REY, Schellekens PTA. Cytotoxic activity of human lymphocyes: quantitative analysis of T cell and K cell cytotoxicity, revealing enzyme-like kinetics. J Immunol 1977;119: 150714.
  • 14
    Khanna R, Burrows JM, Steigerwald-Mullen PM, Thomson SA, Kurilla MG, Moss DJ. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr nuclear antigen 1: Implications for viral persistence and tumor surveillance. Virology 1995;214: 6337.
  • 15
    LeFever AV, Truitt RL. Kinetic analysis of cloned cytotoxic T lymphocyte reactivity against normal and leukemic target cells. J Immunogenet 1986;13: 27585.
  • 16
    Takebe Y, Seiki M, Fujisawa J-I et al. SRα promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 1988;8: 46672.
  • 17
    Clay TM, Custer MC, Saches J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163: 513.
  • 18
    Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996;272: 175562.
  • 19
    Blaese M, Culver K, Miller AD et al. T lymphpocyte-directed gene therapy for ADA SCID: initial trial results after 4 years. Science 1995;270: 47580.
  • 20
    Ettinghausen SE, Rosenberg SA. Clinical trials of immunotherapy utilizing cytotoxic cells. In: SitkovskyMV, HenkartPA, eds. Cytotoxic Cells: Recognition, Effector Function, Generation, and Methods. Boston: Birkhäuser, 1993, 40735.
  • 21
    Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323: 5708.
  • 22
    Cooper LJN, Kalos M, Lweinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type I into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000;74: 820712.
  • 23
    LeFever AV, Piaskowski V, Casper JT, Truitt RL. Kinetic analysis of human IL-2 activated cytotoxic cells. Immunopharmacol Immunotoxicol 1991;13: 14768.
  • 24
    LeFever AV, Truitt RL. Kinetic analysis of Qa-1-specific cloned cytotoxic T lymphocytes: lytic parameters and evaluation of cellular inhibition. Scand J Immunol 1987;25: 54153.
  • 25
    Flores RV, Gilmer PJ. Differential recognition and lysis of EL4 target cells by cytotoxic T cells: differences in K-2Kb antigenic density and cytoskeletal proteins. J Immunol 1984;132: 276774.
  • 26
    Orentas RJ, Lemas MV, Mullin MJ, Colombani PM, Schwarz K, Ambinder RF. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J Hematother 1998;7: 25761.